ET-02 is a CRISPR-based gene-editing therapy to produce Universal Chimeric Antigen Receptor T cell Therapy (U-CAR-T). One of the most exciting treatment breakthroughs in recent years, autologous CAR-T therapies have been approved to treat multiple cancers. By knocking out selected genes involved in immunogenicity, it is possible to produce U-CAR-T from healthy donors as an “off-the-shelf” product to treat cancer patients, potentially resulting in readily availability, more consistent quality and lower cost.
We are developing novel gene-editing technology-based therapies to treat selected diseases. To that end, we have also been developing in vivo drug delivery platforms, including virus-based systems and lipid nanoparticles.
Headquarters
EdiGene Inc.
Building No.22, Kexueyuan Road, Changping Distriction, Beijing, China
Guangzhou Branch
广州辑因医疗科技有限公司
Building 10, No.6, Nanjianger Road, Zhujiang Street, Nansha Distriction, Guangzhou, China
USA Branch
EDIGENE BIOTECHNOLOGY USA INC.
245 FIRST STREET, RIVERVIEW II, 18TH FLOORCAMBRIDGE, MA 02142 USA
Contact Us
Tel:010-8073 3899
E-mail:media@edigene.com